📊 LONA Key Takeaways
Is LeonaBio, Inc. (LONA) a Good Investment?
LeonaBio is a pre-revenue stage biotech company with significant cash burn (-$20.9M per period) and only $32.8M in cash reserves, providing limited runway of approximately 1.5 periods before requiring additional capital. While the balance sheet is unlevered with no debt and strong liquidity ratios, the lack of revenue, negative profitability across all metrics, and substantial insider activity suggest elevated execution and dilution risks that outweigh the modest cash cushion.
LeonaBio is pre‑revenue with deep operating and net losses alongside extremely negative ROE/ROA, indicating poor capital efficiency and no demonstrated path to profitability. While liquidity is acceptable and leverage is minimal, the current cash balance supports only a limited runway given the magnitude of cash burn, implying likely financing/dilution risk absent rapid progress toward revenue or material cost cuts.
LeonaBio, Inc. Key Strengths (LONA)
- Strong cash position of $32.8M with minimal debt (0x debt/equity ratio)
- Excellent liquidity ratios (10.38x current ratio) provide near-term operational flexibility
- Low capital intensity ($33K capex) reduces infrastructure burden
- $69.3M cash provides near‑term liquidity
- Zero long‑term debt and 0.00x debt/equity reduce solvency risk
- Current and quick ratios of 1.88x indicate adequate short‑term coverage
LONA Stock Risks: LeonaBio, Inc. Investment Risks
- Pre-revenue stage with unproven commercial viability and no market validation
- Critical cash runway of approximately 1.5-2 periods at current burn rate of -$20.9M per period
- Substantial insider activity (20 Form 4 filings in 90 days) suggests leadership changes or stock sales indicating potential concerns
- No revenue; business viability not yet validated
- High cash burn (OCF -$45.7M; operating loss -$102.3M) implies dilution/financing risk within ~1–2 years
- Extremely negative ROE (-380%) and ROA (-114.6%) signal poor capital efficiency and potential going‑concern pressure
Key Metrics to Watch
- Revenue initiation and growth trajectory
- Quarterly cash burn rate and available runway remaining
- Capital raising activities and dilution impact on existing shareholders
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
LeonaBio, Inc. (LONA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.38x current ratio provides a solid financial cushion.
LONA Profit Margin, ROE & Profitability Analysis
LONA vs Healthcare Sector: How LeonaBio, Inc. Compares
How LeonaBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LeonaBio, Inc. Stock Overvalued? LONA Valuation Analysis 2026
Based on fundamental analysis, LeonaBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LeonaBio, Inc. Balance Sheet: LONA Debt, Cash & Liquidity
LONA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: LeonaBio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-25.19 indicates the company is currently unprofitable.
LONA Revenue Growth, EPS Growth & YoY Performance
LeonaBio, Inc. Dividends, Buybacks & Capital Allocation
LONA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for LeonaBio, Inc. (CIK: 0001620463)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LONA
What is the AI rating for LONA?
LeonaBio, Inc. (LONA) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LONA's key strengths?
Claude: Strong cash position of $32.8M with minimal debt (0x debt/equity ratio). Excellent liquidity ratios (10.38x current ratio) provide near-term operational flexibility. ChatGPT: $69.3M cash provides near‑term liquidity. Zero long‑term debt and 0.00x debt/equity reduce solvency risk.
What are the risks of investing in LONA?
Claude: Pre-revenue stage with unproven commercial viability and no market validation. Critical cash runway of approximately 1.5-2 periods at current burn rate of -$20.9M per period. ChatGPT: No revenue; business viability not yet validated. High cash burn (OCF -$45.7M; operating loss -$102.3M) implies dilution/financing risk within ~1–2 years.
What is LONA's revenue and growth?
LeonaBio, Inc. reported revenue of N/A.
Does LONA pay dividends?
LeonaBio, Inc. does not currently pay dividends.
Where can I find LONA SEC filings?
Official SEC filings for LeonaBio, Inc. (CIK: 0001620463) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LONA's EPS?
LeonaBio, Inc. has a diluted EPS of $-1.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LONA's fundamental grade?
Based on our AI fundamental analysis in May 2026, LeonaBio, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LONA stock overvalued or undervalued?
Valuation metrics for LONA: ROE of -66.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LONA's AI grade for 2026?
Our dual AI analysis gives LeonaBio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LONA's free cash flow?
LeonaBio, Inc.'s operating cash flow is $-20.9M, with capital expenditures of $33.0K.
How does LONA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -66.8% (avg: 15%), current ratio 10.38 (avg: 2).